Ards Research Analysis
Q1 2026 ARDS research consolidated a precision, biology-first paradigm. A multicentre bedside panel (PHIND) enabled ~1-hour inflammatory subphenotyping with strong prognostic separation, aligning with infrastructure (BIOWARE) and longitudinal metabolomics that stratified risk and treatment response. Preventive therapeutics advanced with a randomized signal for perioperative ARDS reduction using sivelestat. Mechanistic work converged on host-directed pathways—ferroptosis/ferritinophagy (IL-27–NCO